ライフサイエンスコーパス: neurofibromatosis

1 rent orbital schwannoma without evidence for neurofibromatosis.

2 potential tumor suppressor with relevance to neurofibromatosis.

3 g to determine tumor burden in patients with neurofibromatosis.

4 nd most common neurocutaneous syndrome after neurofibromatosis.

5 in SDHB (n = 2), SDHD (n = 3), RET (n = 5), neurofibromatosis 1 (n = 1), and myc-associated factor X

6 negative Ras-MAPK-ERK regulator linked to a neurofibromatosis 1 (NF-1)-like human syndrome; however,

7 he phosphatase and tensin homolog (Pten) and neurofibromatosis 1 (Nf1) genes recently were found to b

8 Historically, neurofibromatosis 1 (NF1) has been inextricably linked w

9 arning to rut mutants, whereas expression of Neurofibromatosis 1 (NF1) in alpha/beta neurons is suffi

10 of children develop PA in the context of the neurofibromatosis 1 (NF1) inherited tumor predisposition

11 Lack of expression of neurofibromin in neurofibromatosis 1 and its lethal derivative, malignant

12 Neurofibromatosis 1 is a hereditary syndrome characteriz

13 n EVH [Ena/Vasp homology] domain 1) and NF1 (neurofibromatosis 1) genes underlie clinically related h

14 yndrome, tuberous sclerosis complex 1 and 2, neurofibromatosis 1, phosphatase and tensin homolog, and

15 Children with neurofibromatosis-1 (NF1) are at risk for developing num

16 In this study, we used neurofibromatosis-1 (NF1) as a model system to elucidate

17 To study the role of the neurofibromatosis-1 (NF1) gene in mammalian brain develo

18 ious studies from our laboratories have used neurofibromatosis-1 (NF1) genetically engineered mouse (

19 We investigated the pathophysiology of neurofibromatosis-1 (NF1) in Drosophila melanogaster by

20 ommon clinical problems in children with the neurofibromatosis-1 (NF1) inherited cancer syndrome.

21 Neurofibromatosis-1 (NF1) is a common tumor predispositi

22 ma resulting from either inactivation of the neurofibromatosis-1 (Nf1) tumor suppressor gene or const

23 In this regard, mutational inactivation of neurofibromatosis-1 (NF1), tuberous sclerosis complex (T

24 somal dominant human disorder that resembles Neurofibromatosis-1 (NF1).

25 ients and are a major contributing factor to neurofibromatosis-1 patient mortality and morbidity.

26 ession was also determined in KIT mutant and neurofibromatosis-1-associated GIST, and complex II acti

27 It is now known that neurofibromatosis-1-associated GISTs are SDHB-positive,

28 In patients with neurofibromatosis, 18F-FDG-PET demonstrated its applicat

29 the inherited cancer predisposition syndrome neurofibromatosis 2 (NF2) develop several central nervou

30 s bearing a loss-of-function mutation in the neurofibromatosis 2 (NF2) gene require MLK3.

31 Merlin, encoded by the Neurofibromatosis 2 (NF2) gene, is a multifunctional tum

32 Inactivating mutations of the neurofibromatosis 2 (NF2) gene, NF2, result predominantl

33 ation of Stat-3 by a mechanism involving the neurofibromatosis 2 (NF2) gene.

34 Neurofibromatosis 2 (NF2) is an inherited cancer syndrom

35 Mutations of the neurofibromatosis 2 (NF2) tumor suppressor gene have fre

36 We further show that the Neurofibromatosis 2 (Nf2) tumor suppressor inhibits Yap

37 The neurofibromatosis 2 (NF2) tumor suppressor protein, schw

38 is 1 (NF1) has been inextricably linked with neurofibromatosis 2 (NF2).

39 Here we show that the tumor suppressor neurofibromatosis 2 (Nf2; merlin) limits the expansion o

40 the tumor suppressor Merlin, encoded by the neurofibromatosis 2 gene.

41 we isolated earlier as an interactor of the neurofibromatosis 2 protein merlin, was independently id

42 er), a homolog of the human tumor suppressor neurofibromatosis 2, is required to coordinate prolifera

43 ion as a mediator of pathologies relevant to Neurofibromatosis 2.

44 The Neurofibromatosis-2 (NF2) tumor suppressor merlin negati

45 association of juvenile xanthogranuloma with neurofibromatosis and chronic juvenile myeloid leukemia

46 These disorders, which include neurofibromatosis and Noonan and Legius syndromes, harbo

47 sus on the genetic and clinical diagnosis of neurofibromatosis and Proteus syndrome has allowed advan

48 sis Colorectal Cancer, Huntington's Disease, Neurofibromatosis and Sickle Cell Anaemia.

49 growth of neurofibromas in a mouse model of neurofibromatosis and that genetic and pharmacological i

50 ses, including Fanconi anemia, hemophilia B, neurofibromatosis, and phenylketonuria, can be caused by

51 Children with neurofibromatosis are reported separately.

52 s within the Department of Defense-sponsored Neurofibromatosis Clinical Trials Consortium.

53 multiple sclerosis, Guillain-Barre disease, neurofibromatosis, diseases of the neuromuscular junctio

54 Individuals with neurofibromatosis I (NF1) are at increased risk of devel

55 Von Recklinghausen neurofibromatosis is a common autosomal dominant genetic

56 Von Recklinghausen neurofibromatosis is caused by mutations in the NF1 gene

57 t neurofibroma formation in individuals with neurofibromatosis might result in part from a Ras-PI3K-A

58 ling contributes to neurofibroma growth in a neurofibromatosis mouse model (Nf1(fl/fl);Dhh-Cre) or in

59 for children with an intracranial tumour and neurofibromatosis; nausea and vomiting (75%), headache (

60 Neurofibromatosis (NF) encompasses a group of distinct g

61 1 (MEN1), von Hippel Lindau (VHL) syndrome, neurofibromatosis (NF-1), and possibly tuberous sclerosi

62 fiers of glioma risk in patients with type I neurofibromatosis (NF1) could help support personalized

63 Type I neurofibromatosis (NF1) is caused by mutations in the NF

64 The human disease von Recklinghausen's neurofibromatosis (Nf1) is one of the most common geneti

65 It is not related to neurofibromatosis (NF1), nor is it associated with vascu

66 on the recent clinical insights into type I neurofibromatosis (NF1), the most common geno-oculo-derm

67 th disorders such as Legius syndrome, type 2 neurofibromatosis (NF2), and multiple lentigenes syndrom

68 usually occurring in individuals with type 2 neurofibromatosis (NF2).

69 a dermatologic disorder, intraoral signs of neurofibromatosis occur quite commonly.

70 stance commonly referred to as "orbitofacial neurofibromatosis" (OFNF).

71 We found that neurofibromatosis- or retinitis pigmentosa-causing mutat

72 targeted therapies have become a reality for neurofibromatosis patients, and hold substantial promise

73 esions in a cohort of 49 children with JMML, neurofibromatosis phenotype (and thereby NF1 mutation) w

74 This effort, known as the Neurofibromatosis Preclinical Consortium (NFPC), was est

75 the numerous growths that covered his body: neurofibromatosis, Proteus syndrome, and a combination o

76 dor Hospital presented disfigurements due to neurofibromatosis, severe burns, or ballistic trauma and

77 (male individuals only 30%; mixed sex 22%), neurofibromatosis type 1 (18%), Down's syndrome (16%), N

78 ccinate dehydrogenase B-D mutation (n = 21), neurofibromatosis type 1 (n = 1), RET (n = 1), no germli

79 edictors of outcome in patients with/without neurofibromatosis type 1 (NF-1) associated MPNST.

80 In neurofibromatosis type 1 (NF-1), malignant transformatio

81 in children with refractory solid tumors and neurofibromatosis type 1 (NF1) -related plexiform neurof

82 Neurofibromatosis type 1 (NF1) and Legius syndrome are r

83 ances in our understanding of the biology of neurofibromatosis type 1 (NF1) and neurofibromatosis typ

84 Multiple tumors are a hallmark of neurofibromatosis type 1 (NF1) and type 2 (NF2) and schw

85 ifferent VA testing methods in children with neurofibromatosis type 1 (NF1) and/or optic pathway glio

86 Children with neurofibromatosis type 1 (NF1) are increasingly recogniz

87 Children with neurofibromatosis type 1 (NF1) are predisposed to juveni

88 Children with neurofibromatosis type 1 (NF1) are prone to learning and

89 th a broad range of signs typically found in neurofibromatosis type 1 (NF1) but no detectable NF1 ger

90 etermine the risk of cancer in patients with neurofibromatosis type 1 (NF1) by cancer type, age, and

91 Children with neurofibromatosis type 1 (NF1) cancer predisposition syn

92 Patients with neurofibromatosis type 1 (NF1) carry approximately a 10%

93 Patients with neurofibromatosis type 1 (NF1) develop benign plexiform

94 Children with neurofibromatosis type 1 (NF1) develop low-grade brain t

95 Individuals with neurofibromatosis type 1 (NF1) frequently exhibit cognit

96 The neurofibromatosis type 1 (Nf1) gene encodes a GTPase act

97 The neurofibromatosis type 1 (NF1) gene encodes the GTPase-a

98 In this review, we highlight advances in neurofibromatosis type 1 (NF1) genetically engineered mo

99 e imaging for an optic pathway glioma and/or neurofibromatosis type 1 (NF1) had multiple 6 x 6 mm vol

100 Individuals with neurofibromatosis type 1 (NF1) have a high incidence of

101 Persons with neurofibromatosis type 1 (NF1) have a predisposition for

102 found that loss of the tumor suppressor gene neurofibromatosis type 1 (Nf1) increased HSF1 levels and

103 from tumor cells, we demonstrate how loss of neurofibromatosis type 1 (NF1) increases RAS-GTP levels

104 mors (pilocytic astrocytomas) arising in the neurofibromatosis type 1 (NF1) inherited cancer predispo

105 Individuals with the neurofibromatosis type 1 (NF1) inherited cancer syndrome

106 Neurofibromatosis type 1 (NF1) is a common autosomal dom

107 Neurofibromatosis type 1 (NF1) is a common autosomal dom

108 Neurofibromatosis type 1 (NF1) is a common cancer predis

109 Neurofibromatosis type 1 (NF1) is a common genetic disor

110 Neurofibromatosis type 1 (NF1) is a common genetic disor

111 Neurofibromatosis type 1 (NF1) is a common neurodevelopm

112 Neurofibromatosis type 1 (NF1) is a common neurodevelopm

113 Neurofibromatosis type 1 (NF1) is a common neurogenetic

114 Neurofibromatosis type 1 (NF1) is a common neurogenetic

115 Neurofibromatosis type 1 (NF1) is a common tumor-predisp

116 Neurofibromatosis type 1 (NF1) is a dominant genetic dis

117 Neurofibromatosis type 1 (NF1) is a genetic disease caus

118 Neurofibromatosis type 1 (NF1) is a genetic disease that

119 Neurofibromatosis type 1 (NF1) is a genetic disorder res

120 Neurofibromatosis type 1 (NF1) is an autosomal dominant

121 Neurofibromatosis type 1 (NF1) is an inherited disease i

122 The diagnosis of neurofibromatosis type 1 (NF1) is based on 7 clinical cr

123 Neurofibromatosis type 1 (NF1) is characterized by cafe-

124 Neurofibromatosis type 1 (NF1) is one of the most common

125 Neurofibromatosis type 1 (NF1) is the most common geneti

126 Neurofibromatosis type 1 (NF1) is the most common monoge

127 Astrocytoma (glioma) formation in neurofibromatosis type 1 (NF1) occurs preferentially alo

128 Neurofibromatosis type 1 (NF1) patients are predisposed

129 Neurofibromatosis type 1 (NF1) patients develop benign n

130 ival rates and the leading cause of death in neurofibromatosis type 1 (NF1) patients under 40 years o

131 e observation that half of MPNSTs develop in neurofibromatosis type 1 (NF1) patients, subsequent to N

132 Neurofibromatosis type 1 (NF1) predisposes individuals t

133 Neurofibromatosis type 1 (NF1) results from mutations in

134 Neurofibromatosis type 1 (NF1) results from mutations in

135 Vision, quality of life, neurofibromatosis type 1 (NF1) status, and BRAF mutation

136 roma to a malignant sarcoma in patients with neurofibromatosis type 1 (NF1) syndrome remains unclear.

137 Mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene are

138 TOPIC: Children and adults with neurofibromatosis type 1 (NF1), a common autosomal domin

139 Children and adults with neurofibromatosis type 1 (NF1), a common autosomal domin

140 Neurofibromatosis type 1 (NF1), a common genetic disorde

141 tions in the NF1 tumor suppressor gene cause neurofibromatosis type 1 (NF1), a common genetic disorde

142 ris) is one of seven diagnostic criteria for neurofibromatosis type 1 (NF1), a common monogenic disor

143 y the NF1 gene, the mutation of which causes Neurofibromatosis type 1 (NF1), a genetic disorder chara

144 metastatic sarcomas that are associated with neurofibromatosis type 1 (NF1), a prominent inherited ge

145 sion profiles in iN cells from patients with neurofibromatosis type 1 (NF1), a single-gene multifacet

146 OPG), seen in 15% to 20% of individuals with neurofibromatosis type 1 (NF1), account for significant

147 Neurofibromatosis type 1 (NF1), an NCFC syndrome, is cau

148 an important ocular finding in patients with neurofibromatosis type 1 (NF1), and early detection of t

149 n, in which loss-of-function mutations cause Neurofibromatosis Type 1 (NF1), contributes to the major

150 In neurofibromatosis type 1 (NF1), deregulation of Ras sign

151 on inherited cancer predisposition syndrome, neurofibromatosis type 1 (NF1), the prevalence of these

152 ging a genetically engineered mouse model of neurofibromatosis type 1 (NF1)-associated optic glioma,

153 omas, OPGs), especially in children with the neurofibromatosis type 1 (NF1)-inherited tumor predispos

154 tions in the NF1 tumor suppressor gene cause Neurofibromatosis type 1 (NF1).

155 oplasms that commonly occur in patients with neurofibromatosis type 1 (NF1).

156 ur sporadically in a subset of patients with neurofibromatosis type 1 (NF1).

157 y-resistant tumours arising in patients with neurofibromatosis type 1 (NF1).

158 ng RAS activity via promoting degradation of neurofibromatosis type 1 (NF1).

159 rments are one of the many manifestations of neurofibromatosis type 1 (NF1).

160 ed autistic trait burden in individuals with neurofibromatosis type 1 (NF1).

161 and is mutated in humans with the condition neurofibromatosis type 1 (NF1).

162 As arising sporadically and in patients with neurofibromatosis type 1 (NF1).

163 ect tumor susceptibility in a mouse model of neurofibromatosis type 1 (NF1).

164 ith pseudarthrosis (PA), are associated with neurofibromatosis type 1 (NF1).

165 auses substantial morbidity in patients with neurofibromatosis type 1 (NF1).

166 kin hyperpigmentation are early hallmarks of neurofibromatosis type 1 (NF1).

167 l feature of the common neurogenetic disease neurofibromatosis type 1 (NF1).

168 benign neurofibromas (BNFs) in patients with neurofibromatosis type 1 (NF1).

169 causing the genetic neurocutaneous disorder neurofibromatosis type 1 (NF1).

170 te new treatments for tumors associated with neurofibromatosis type 1 (NF1).

171 erlie the prevalent familial cancer syndrome neurofibromatosis type 1 [1].

172 Although many manifestations of neurofibromatosis type 1 affect the nervous system, othe

173 d, such as Angelman syndrome, Rett syndrome, Neurofibromatosis Type 1 and Fragile X syndrome, the cla

174 arly-phase data suggested that children with neurofibromatosis type 1 and inoperable plexiform neurof

175 PK kinase (MEK) 1 and 2, in children who had neurofibromatosis type 1 and inoperable plexiform neurof

176 ant signaling pathway that is deregulated in neurofibromatosis type 1 and malignant peripheral nerve

177 initially thought to have NS was revised to neurofibromatosis type 1 based on an NF1 nonsense mutati

178 A. beta-catenin modulation in neurofibromatosis type 1 bone repair: therapeutic implic

179 Neurofibromatosis type 1 is a relatively common inherite

180 Neurofibromatosis type 1 is a tumor-predisposing genetic

181 Neurofibromatosis type 1 is due to a reduction of the tu

182 Neurofibromatosis type 1 is the most commonly inherited

183 On occasion, neurofibromas in neurofibromatosis type 1 may be present on the lid, brow

184 e, the association of clinical symptoms with neurofibromatosis type 1 might not be appreciated.

185 Neurofibromatosis type 1 results from autosomal dominant

186 years after CRT correlated with patient age, neurofibromatosis type 1 status, tumor location and volu

187 of Nf1, the Ras GTPase gene underlying human neurofibromatosis type 1 syndrome, causes lens dysgenesi

188 at occur sporadically or in association with neurofibromatosis type 1 syndrome.

189 ildren with an OPG (sporadic or secondary to neurofibromatosis type 1) who were cooperative for visua

190 n (phosphatase with tensin homolog) and Nf1 (neurofibromatosis type 1), enhanced filopodial motility.

191 n in the NF1 tumor suppressor gene underlies Neurofibromatosis type 1, a complex disease that enhance

192 that encompass NF1 cause 5%-10% of cases of neurofibromatosis type 1, and individuals with microdele

193 enetics, and cancer screening guidelines for neurofibromatosis type 1, Beckwith-Wiedemann syndrome/ h

194 essor NF1 contributes to the pathobiology of neurofibromatosis type 1, but a related role has not bee

195 nd to provide optimum care for patients with neurofibromatosis type 1, clinicians must be aware of th

196 r muscles, lymphedema-distichiasis syndrome, neurofibromatosis type 1, congenital myasthenic syndrome

197 of neurofibromin 1 (Nf1), a gene mutated in neurofibromatosis type 1, unlocked a latent oligodendroc

198 asionally been described in association with neurofibromatosis type 1, whereas an association with ne

199 enotype is reminiscent of the human disorder neurofibromatosis type 1, which is characterized by disf

200 Studies of human neurofibromatosis type 1-associated tumors suggest that

201 Neurofibromatosis type 1-derived Schwann cells isolated

202 We report 4 cases of pediatric OPGs (2 neurofibromatosis type 1-related and 2 sporadic cases) t

203 so tested selumetinib using a mouse model of neurofibromatosis type 1-related neurofibroma.

204 l therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas

205 the more common ophthalmic manifestations of neurofibromatosis type 1.

206 of cases, primarily in the optic nerve, with neurofibromatosis type 1.

207 r in association with the inherited syndrome neurofibromatosis type 1.

208 ith a heterozygous mutation of Nf1 linked to neurofibromatosis type 1.

209 e delay observed in patients with IBMPFD and neurofibromatosis type 1.

210 e plexiform neurofibroma microenvironment of neurofibromatosis type 1.

211 cur sporadically, after radiotherapy, and in neurofibromatosis type 1.

212 had prior chemotherapy, and 13 patients had neurofibromatosis type 1.

213 n myeloid malignancies from 10 children with neurofibromatosis type 1.

214 contribute to the neoplastic development of neurofibromatosis type 1.

215 onship to choroidal nodules in patients with neurofibromatosis type 1.

216 s) develop sporadically or in the context of neurofibromatosis type 1.

217 iology of neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) as they relate to the dev

218 INTRODUCTION: Patients with neurofibromatosis type 2 (NF2) develop bilateral cochleo

219 teral vestibular schwannomas associated with neurofibromatosis type 2 (NF2) experience significant mo

220 n the long arm of chromosome 22 and near the neurofibromatosis type 2 (NF2) gene (22q12) were most fr

221 Mutations in the neurofibromatosis type 2 (NF2) gene cause formation of s

222 Loss of function mutations in the neurofibromatosis Type 2 (NF2) gene, coding for a tumour

223 Neurofibromatosis type 2 (NF2) is a dominantly inherited

224 Neurofibromatosis type 2 (NF2) is a multiple neoplasia s

225 Neurofibromatosis type 2 (NF2) is a tumor predisposition

226 Neurofibromatosis type 2 (NF2) is an autosomal dominant

227 Neurofibromatosis type 2 (NF2) is an autosomal dominant

228 Neurofibromatosis type 2 (NF2) is an autosomal-dominant

229 Neurofibromatosis type 2 (NF2) is caused by mutations in

230 e patient suggests possible association with neurofibromatosis type 2 (NF2) or schwannomatosis.

231 The neurofibromatosis type 2 (NF2) tumor suppressor gene enc

232 Inactivation of the neurofibromatosis type 2 (NF2) tumor suppressor gene fun

233 ort here that liver-specific deletion of the neurofibromatosis type 2 (Nf2) tumor suppressor gene in

234 We previously identified the neurofibromatosis type 2 (NF2) tumor suppressor Merlin a

235 The neurofibromatosis type 2 (NF2) tumor suppressor, Merlin,

236 The neurofibromatosis type 2 (NF2) tumor suppressor, Merlin,

237 The neurofibromatosis type 2 (NF2) tumor-suppressor protein

238 vant targets, we examined the role of YAP in neurofibromatosis type 2 (NF2) using cell and animal mod

239 uirement for the PAKs in the pathogenesis of Neurofibromatosis type 2 (NF2), a dominantly inherited c

240 Neurofibromatosis type 2 (NF2), a dominantly inherited t

241 ions in the merlin tumor suppressor underlie neurofibromatosis type 2 (NF2), a familial autosomal dom

242 function mutations or deletions in NF2 cause neurofibromatosis type 2 (NF2), a multiple tumor forming

243 s of expression of merlin is responsible for neurofibromatosis type 2 (NF2), which is characterized b

244 ene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104

245 ed with increased mortality in patients with neurofibromatosis type 2 (NF2).

246 cally or as part of the hereditary condition neurofibromatosis Type 2 (NF2).

247 refers to an Italian 69 year old woman with neurofibromatosis type 2 and a pancreatic gastrinoma.

248 om 21 vestibular schwannomas associated with neurofibromatosis type 2 and from 22 sporadic schwannoma

249 Ten consecutive patients with neurofibromatosis type 2 and progressive vestibular schw

250 hearing in some, but not all, patients with neurofibromatosis type 2 and was associated with a reduc

251 is a tumor suppressor protein encoded by the neurofibromatosis type 2 gene NF2.

252 omatosis type 1, whereas an association with neurofibromatosis type 2 has never been reported.

253 Neurofibromatosis type 2 is an autosomal-dominant multip

254 Neurofibromatosis type 2 is an inherited autosomal disor

255 The neurofibromatosis type 2 NF2 gene product, merlin, is a

256 Neurofibromatosis type 2 patients develop schwannomas, m

257 The neurofibromatosis type 2 tumor suppressor protein, merli

258 hese actions of ezrin are antagonized by the neurofibromatosis type 2 tumor-suppressor protein merlin

259 examined from an additional 39 patients with neurofibromatosis type 2 who were retrospectively identi

260 erlin/NF2 (moesin-ezrin-radixin-like protein/neurofibromatosis type 2) is a tumor suppressor found to

261 In neurofibromatosis type 2, a dominantly inherited tumor d

262 nd hearing loss is a serious complication of neurofibromatosis type 2, a genetic condition associated

263 umours that occur in patients suffering from neurofibromatosis type 2, all spontaneous schwannomas an

264 xternal ophthalmoplegia, myotonic dystrophy, neurofibromatosis type 2, and basal cell nevus syndrome.

265 first case of coexistence of gastrinoma with neurofibromatosis type 2.

266 ation of schwannoma tumours in patients with neurofibromatosis type 2.

267 aracterized by abnormal vasculature, such as neurofibromatosis type 2.

268 y benign, and are frequently associated with neurofibromatosis type 2.

269 the remainder acquire a de novo mutation for neurofibromatosis type 2.

270 ical findings, and management strategies for neurofibromatosis type 2.

271 taneously or as part of a hereditary disease neurofibromatosis type 2.

272 We also show that KIBRA associates with neurofibromatosis type 2/Merlin in a Ser(539) phosphoryl

273 Neurofibromatosis type I (NF-1), affecting 1: 3000 peopl

274 may occur sporadically, in association with neurofibromatosis type I (NF1 associated) or after radio

275 n tumors encountered in individuals with the neurofibromatosis type I (NF1) cancer predisposition syn

276 In this communication, we report that neurofibromatosis type I (NF1) exon 23a is a novel targe

277 Neurofibromatosis type I (NF1) is a common autosomal dom

278 Neurofibromatosis type I (NF1) is a congenital disorder

279 Neurofibromatosis type I (NF1) is a genetic disorder cau

280 Neurofibromatosis type I (NF1) is a genetic disorder cau

281 Neurofibromatosis type I (Nf1) is a GTPase-activating pr

282 Neurofibromatosis Type I (NF1) is a single-gene disorder

283 Neurofibromatosis type I (NF1) is an autosomal disorder

284 Neurofibromatosis type I (NF1) is one of the most common

285 Mutations in NF1 cause neurofibromatosis type I (NF1), a disorder characterized

286 Neurofibromatosis type I (NF1), caused by the mutation i

287 n a mouse model for learning disabilities in neurofibromatosis type I (NF1).

288 Neurofibromatosis type I (NF1; also known as von Recklin

289 to understanding neurofibroma development in neurofibromatosis type I patients.

290 fragile X, Rett syndrome, Down syndrome, and neurofibromatosis type I suggest that it is possible to

291 ly member, regulates three target pre-mRNAs: neurofibromatosis type I, Fas and HuD.

292 decades ago as a tumor suppressor underlying Neurofibromatosis type II, its precise molecular mechani

293 Individuals with neurofibromatosis type-1 (NF1) can manifest focal skelet

294 oradically or in patients with the inherited neurofibromatosis type-1 (NF1) syndrome.

295 mors (MPNST) develop in approximately 10% of neurofibromatosis type-1 patients and are a major contri

296 Merlin, the Drosophila homolog of the human Neurofibromatosis type-2 (NF2) tumor-suppressor gene, an

297 In humans, mutations in the NF2 gene cause neurofibromatosis type-2 (NF2), a cancer syndrome charac

298 ted tumor predisposition syndrome, including neurofibromatosis types 1 (NF1) and 2 (NF2), familial sc

299 rofibromin, cause the human genetic disorder neurofibromatosis, which is characterized by formation o

300 t of a zebrafish model of von Recklinghausen neurofibromatosis will allow for structure-function anal